These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 16799383)

  • 1. The efficacy of Apligraf in the treatment of diabetic foot ulcers.
    Dinh TL; Veves A
    Plast Reconstr Surg; 2006 Jun; 117(7 Suppl):152S-157S; discussion 158S-159S. PubMed ID: 16799383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Special segment: soft tissue matrices--Apligraf bilayered skin substitute to augment healing of chronic wounds in diabetic patients.
    DeCarbo WT
    Foot Ankle Spec; 2009 Dec; 2(6):299-302. PubMed ID: 20400430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of chronic diabetic lower extremity ulcers with advanced therapies: a prospective, randomised, controlled, multi-centre comparative study examining clinical efficacy and cost.
    Zelen CM; Serena TE; Gould L; Le L; Carter MJ; Keller J; Li WW
    Int Wound J; 2016 Apr; 13(2):272-82. PubMed ID: 26695998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apligraf in the treatment of neuropathic diabetic foot ulcers.
    Edmonds M;
    Int J Low Extrem Wounds; 2009 Mar; 8(1):11-8. PubMed ID: 19189997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bilayered bioengineered skin substitute (Apligraf): a review of its use in the treatment of venous leg ulcers and diabetic foot ulcers.
    Curran MP; Plosker GL
    BioDrugs; 2002; 16(6):439-55. PubMed ID: 12463767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective, randomised, controlled, multi-centre comparative effectiveness study of healing using dehydrated human amnion/chorion membrane allograft, bioengineered skin substitute or standard of care for treatment of chronic lower extremity diabetic ulcers.
    Zelen CM; Gould L; Serena TE; Carter MJ; Keller J; Li WW
    Int Wound J; 2015 Dec; 12(6):724-32. PubMed ID: 25424146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Graftskin treatment of difficult to heal diabetic foot ulcers: one center's experience.
    Sams HH; Chen J; King LE
    Dermatol Surg; 2002 Aug; 28(8):698-703. PubMed ID: 12174061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost effectiveness of Apligraf treatment of diabetic foot ulcers.
    Redekop WK; McDonnell J; Verboom P; Lovas K; Kalo Z
    Pharmacoeconomics; 2003; 21(16):1171-83. PubMed ID: 14594438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innovative therapies in wound healing.
    Shen JT; Falanga V
    J Cutan Med Surg; 2003; 7(3):217-24. PubMed ID: 12704530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Special segment: soft tissue matrices--Bilayered bioengineered skin substitute to augment wound healing.
    DeCarbo WT
    Foot Ankle Spec; 2009 Dec; 2(6):303-5. PubMed ID: 20400431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization of living bilayered cell therapy (Apligraf) for heel ulcers.
    Karr J
    Adv Skin Wound Care; 2008 Jun; 21(6):270-4. PubMed ID: 18525250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Best-practice algorithms for the use of a bilayered living cell therapy (Apligraf) in the treatment of lower-extremity ulcers.
    Cavorsi J; Vicari F; Wirthlin DJ; Ennis W; Kirsner R; O'Connell SM; Steinberg J; Falanga V
    Wound Repair Regen; 2006; 14(2):102-9. PubMed ID: 16630097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and mechanism of bilayered living human skin equivalent (HSE) in treatment of diabetic foot ulcers.
    Brem H; Young J; Tomic-Canic M; Isaacs C; Ehrlich HP
    Surg Technol Int; 2003; 11():23-31. PubMed ID: 12931279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of collagen bioscaffolds, foamed collagen, and living skin equivalents in wound healing.
    Landsman A; Taft D; Riemer K
    Clin Podiatr Med Surg; 2009 Oct; 26(4):525-33. PubMed ID: 19778686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of a bi-layered living cell treatment (Apligraf) in the treatment of venous leg ulcers and diabetic foot ulcers.
    Zaulyanov L; Kirsner RS
    Clin Interv Aging; 2007; 2(1):93-8. PubMed ID: 18044080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial.
    Veves A; Falanga V; Armstrong DG; Sabolinski ML;
    Diabetes Care; 2001 Feb; 24(2):290-5. PubMed ID: 11213881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced biological therapies for diabetic foot ulcers.
    Kirsner RS; Warriner R; Michela M; Stasik L; Freeman K
    Arch Dermatol; 2010 Aug; 146(8):857-62. PubMed ID: 20713816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue engineering in wound repair.
    Falanga VJ
    Adv Skin Wound Care; 2000; 13(2 Suppl):15-9. PubMed ID: 11074998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Confirmatory data from EU study supports Apligraf for the treatment of neuropathic diabetic foot ulcers.
    Steinberg JS; Edmonds M; Hurley DP; King WN
    J Am Podiatr Med Assoc; 2010; 100(1):73-7. PubMed ID: 20093548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers.
    Langer A; Rogowski W
    BMC Health Serv Res; 2009 Jul; 9():115. PubMed ID: 19591680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.